Artelo Biosciences (ARTL) investor relations material

Executive summary

• Focused on developing therapeutics targeting lipid-signaling pathways, with three main programs: ART27.13 (cancer anorexia, Phase 2a), ART26.12 (FABP5 inhibitor, Phase 1), and ART12.11 (CBD cocrystal, preclinical), all showing promising efficacy and safety data.

• ART26.12 advanced toward a Phase 1 multiple ascending dose study, with first-in-human data showing favorable safety, tolerability, pharmacokinetics, and pain relief in osteoarthritis and spinal cord injury models.

• ART27.13 interim Phase 2 CARES data showed significant weight gain, lean mass, and activity improvements in cancer patients, especially at the highest dose, with a favorable safety profile.

• ART12.11, a patented CBD:TMP cocrystal, is advancing toward human studies, with preclinical data supporting improved bioavailability and consistent exposure.

• No revenue generated to date; expects continued losses as R&D progresses.

Financial highlights

• Net loss for six months ended June 30, 2026: $5.4 million, compared to $5.6 million for the same period in 2025; Q2 2026 net loss was $2.4 million ($0.89 per share), down from $3.2 million in Q2 2025.

• Operating expenses for six months ended June 30, 2026: $5.2 million, down from $5.5 million year-over-year.

• Research and development expenses were $0.9 million for Q2 2026, down from $1.9 million in Q2 2025.

• Cash and cash equivalents as of June 30, 2026: $4.2 million, up from $0.6 million at December 31, 2025.

• Weighted average shares outstanding for six months ended June 30, 2026: 1.7 million.

Outlook and guidance

• Expects continued R&D and general and administrative expenses, with future increases tied to clinical development and available funding.

• Preparing to initiate a Phase 1 multiple ascending dose study for ART26.12 in Q4 2026.

• Advancing ART12.11 toward human clinical studies in the first half of 2026, with regulatory guidance supporting accelerated pathways.

• Evaluating ART27.13 for additional indications, including as a GLP-1 companion therapy for muscle preservation.

• Substantial doubt exists about ability to continue as a going concern within one year without additional funding.